Thomasville National Bank Cuts Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Thomasville National Bank reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 45.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 107,139 shares of the biopharmaceutical company's stock after selling 89,340 shares during the quarter. Thomasville National Bank's holdings in Gilead Sciences were worth $12,005,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. FMR LLC boosted its stake in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Gilead Sciences by 3.1% in the 4th quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company's stock valued at $3,293,822,000 after purchasing an additional 1,058,331 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company's stock valued at $2,608,337,000 after purchasing an additional 749,047 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $1,789,254,000. Finally, Northern Trust Corp boosted its stake in shares of Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 1.8%

Shares of NASDAQ:GILD traded down $2.07 during mid-day trading on Friday, hitting $109.98. The company had a trading volume of 8,148,740 shares, compared to its average volume of 7,744,306. The firm has a fifty day moving average price of $105.67 and a 200 day moving average price of $102.26. The company has a market capitalization of $136.81 billion, a PE ratio of 297.24, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a one year low of $62.69 and a one year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion during the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Gilead Sciences's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.32) EPS. As a group, research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and lifted their target price for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Oppenheimer cut their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Morgan Stanley lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now directly owns 620,268 shares of the company's stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the transaction, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,000 shares of company stock worth $4,630,310. 0.27% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.